Key Development
Vietnam’s Ministry of Health is moving toward a model that tracks medical devices not only at the final point of purchase, but across their full journey from importation and licensing to taxation, tendering, hospital use and insurance payment.
At an October 1, 2026 briefing, the Ministry’s Infrastructure and Medical Device Administration said proposed regulatory changes are being developed around lifecycle and whole-supply-chain management. The Ministry is also studying greater interoperability between government databases and device-level identification to improve traceability.
This would build on an existing pricing framework rather than start from zero. Vietnam already requires price declaration for specified devices. Circular 29/2024/TT-BYT identifies nine device categories covering 60 detailed product names, including dialysis machines, ventilators, anesthesia systems, patient monitors, infusion equipment, defibrillators, electrosurgical units and X-ray systems. In August 2026, the Ministry also instructed provincial authorities to strengthen price declaration, publication and monitoring for unusual price movements.
Why It Matters
- A medical device does not have one economically meaningful price. Import value, declared price, listed price and tender price represent different stages and cost structures.
- Fragmented data weaken procurement benchmarks. Without linkage across customs, tax, regulatory and hospital systems, price differences are difficult to explain reliably.
- The regulatory model is moving toward anomaly detection. Authorities have been asked to flag unusually large differences between companies or price changes inconsistent with market and cost factors.
- Transparency is not the same as uniform pricing. The Ministry explicitly cautioned that declared or listed prices cannot simply be treated as tender prices because procurement economics include additional factors.
Healthcare Insight Analysis
Healthcare Insight believes the key strategic concept is price traceability.
Today, different parts of the system may each hold one part of the economic picture.
Customs can see import values.
Price databases can see declarations.
Hospitals see tender offers.
Insurers see reimbursed costs.
But unless those records can be connected to the same model, configuration and supply pathway, more data do not automatically produce better pricing intelligence.
The emerging model could instead create a traceable sequence:
manufacturer/import value → importer → distributor → bundled services → hospital tender → installation → maintenance → reimbursement.
That changes the regulatory question.
Instead of asking:
“Why did the hospital pay more than the import price?”
the more useful question becomes:
“What created the difference, and can each component be justified?”
That distinction is critical.
Medical-device procurement often incorporates transportation, installation, training, warranties, maintenance, replacement parts, software and financing or payment terms. The Ministry’s August guidance already requires businesses offering bundled packages to disclose the device price and associated service costs more clearly.
A simplistic comparison between customs value and hospital purchase price could therefore create false signals.
It could also generate a harmful procurement response: hospitals become reluctant to buy advanced equipment because any price differential appears suspicious even when it reflects legitimate lifecycle services.
The better opportunity is to build comparable total-cost data.
A scanner with a lower purchase price but frequent downtime, expensive proprietary parts and weak service coverage may ultimately cost the health system more than a higher-priced system with strong uptime and predictable maintenance.
That is the next stage of mature medtech procurement.
The objective should move from lowest acquisition price toward best lifecycle value.
Device-level identifiers could be especially important here because medical equipment is difficult to benchmark by brand name alone. Different software packages, detectors, accessories, warranties and service levels can materially alter value even within the same product family.
Without configuration-level matching, digital transparency risks producing misleading comparisons.
Market Implications
Hospitals: purchasing decisions may increasingly require total-cost-of-ownership analysis rather than acquisition-price comparison alone.
Distributors: additional supply-chain layers will face greater pressure to demonstrate the economic value they add.
Manufacturers: companies with strong service networks, transparent lifecycle economics and high uptime could gain competitive advantage.
Regulators: integrated data can support targeted investigation of outliers rather than broad price suppression.
ANALYTICAL MATRIX
| Dimension | Current Challenge | Emerging Model | Key Risk |
|---|---|---|---|
| Price data | Fragmented | End-to-end linkage | Poor data standardization |
| Identification | Configuration difficult to compare | Device-level traceability | Apples-to-oranges comparisons |
| Procurement | Acquisition-price focus | Lifecycle economics | Treating declaration as tender ceiling |
| Distribution | Multiple layers | Value-added traceability | Removing legitimate services |
| Oversight | Declaration/listing | Anomaly detection | Transparency becoming de facto price control |
The most useful future KPIs will not be limited to average purchase price. They should include total cost of ownership, equipment uptime, lifecycle maintenance expenditure and the share of price differentials that can be transparently explained by identifiable services.
If Vietnam gets this architecture right, regulators will know more than how much a hospital paid for a machine. They will understand how that price was created — which is a much stronger foundation for controlling healthcare costs without undermining competition, service quality or technology access.